Other autophagy inducers like mTOR inhibitors, BH3 mimetics, the receptor tyrosine kinase inhibitor sorafenib, the proteasome inhibitor bortezomib, the antigout agent colchicine, the nonreducing disaccharide trehalose, and 2-deoxyglucose have entered clinical phase trials against cancer and neurodegenerative diseases. Here, MTOR is linked to cancer.